I came to Rutgers Cancer Institute of New Jersey in 2005 from the Dana-Farber Cancer Institute/Harvard Medical School where I was an instructor in medicine and staff physician. I started my medical training at Yale University, where I graduated from with both an MD and a PhD in cell biology. I then completed a medical residency at the Brigham and Women’s Hospital in Boston and served as a Chief Medical Resident. This was followed by a fellowship in medical oncology at the Dana-Farber Cancer Institute.
With a research interest in breast cancer biology and DNA repair, I am currently exploring how DNA repair defects in cancers can be exploited to develop novel effective treatments. I am also active in applying next-generation sequencing technology to identify specific genomic changes in cancers that can be therapeutically targeted. We work closely with computational scientists in interpreting large scale cancer genome data As a physician/scientist I run a basic science laboratory focused on cancer genomics and breast cancer biology and also see patients in the Stacy Goldstein Breast Cancer Center. I also run the RCINJ Molecular Tumor Board. In the clinic, I work collaboratively with experts across multi-disciplines and have the opportunity to put theory into practice as we aim to develop the next generation of targeted treatments for breast cancer. Working with a team of radiation oncologists, surgical oncologists, nurses, social workers, genetic specialists and others, I help patients understand their specific disease and their treatment options so that they can make informed decisions.
I am the author or co-author of more than 100 publications and am an Associate Editor for JCO- Precision Oncology.
Learn more about Dr. Ganesan's work:
Breast cancer, BRCA1/2, triple-negative breast cancer, breast cancer biology, clinical trials, rare cancers, precision medicine
Hero Award, Triple Negative Breast Cancer Foundation
National Cancer Institute, Howard Temin Award, 2004
Howard Hughes Medical Institute, Postdoctoral Research Fellowship, 1999
Ratings and Reviews
Based on 23 reviews
Shows respect for what you say
Spends enough time with you
Provider explains things in way you understand
Provider listens carefully to you
Gives easy to understand instructions
November 11, 2022
*Dr. Ganesan is an excellent care giver/provider. If there had been any worries or concerns on my part, they would have been addressed.
October 11, 2022
*Dr. Ganesan & *Dr. Hafty - Great.
March 28, 2022
This was a 5 year follow up after chemo treatment. I am having some back issues and he was right on it and I got an x-ray that day. With having had triple - this really eased my worries. He also was quick to call me. He is just excellent.
Accepted Health Plan information is only as accurate as the most current information submitted. Prior to your appointment, it is advisable to verify with your insurance company they are still a participating plan prior to receiving services or care. Each plan is different and some provide different levels of coverage that could make a difference in your out-of-pocket costs. It is always best for the patient receiving care to contact their insurance company to obtain more information.
Consumer Health Plan
Horizon NJ Health
Articles and Press
Unraveling of Genetic Mechanism behind Tumor Formation may Improve Targeted Treatment for Cancer Patients
An international team of researchers, including Shridar Ganesan, MD, PhD have found new opportunities to improve diagnostics and targeted therapy for many cancer patients. Read more
A George Mason University and Rutgers Cancer Institute of New Jersey collaboration received the U.S. Army’s Breast Cancer Research Program (BCRP) Breakthrough Award to quickly confirm if an identified HER2 biomarker can indicate success likelihood of personalized breast cancer treatments. Read more
Dr. Shridar Ganesan Discusses Molecular DNA Repair Mechanisms & DNA Repair Cancer Research
Colon Microbes Provide Clues to Favorable Treatment Options in a Subset of Colon Cancer Patients
Investigators from Rutgers Cancer Institute led a collaborative study to examine the patterns of druggable oncogenic fusions in colon cancer specimens including microsatellite-stable and unstable (MSI) tumors. Read more